Robert S. Negrin

Robert S. Negrin, MD is a Professor of Medicine specializing in Blood and Marrow Transplantation and Cellular Therapy at Stanford University School of Medicine. He served as Chief of the Division of Blood and Marrow Transplantation at Stanford University from 2000-2020 and continues to maintain an active research program and clinical practice. He is a member of Bio-X, the Maternal & Child Health Research Institute (MCHRI), and the Stanford Cancer Institute.

Dr. Negrin's educational background includes a BA in Biochemistry from UC Berkeley (1977), an MD from Harvard Medical School (1984), followed by internship, residency, and fellowship training at Stanford University School of Medicine. He joined the Stanford faculty in 1990 and has built a distinguished career in hematopoietic cell transplantation and immunology.

His research focuses on cellular immunology, particularly understanding complex biological reactions such as graft versus host and graft versus tumor reactions. He has developed innovative animal models using bioluminescent techniques to track tumor growth and immune responses. His laboratory investigates the clinical utility of expanded cytotoxic cells for immunotherapy, the interaction between cytotoxic effector cells and tumor targets, the role of regulatory T cells, and the mechanisms of cell-mediated cytotoxicity.

Dr. Negrin has authored over 300 original papers, 40 book chapters, and a book. His clinical expertise includes blood and marrow transplantation and hematology, with a focus on treating hematologic malignancies and managing transplant complications.

• Doris Duke Distinguished Clinical Scientist Award recipient
• Member of the Association of American Physicians
• Former President of both the International Society of Cellular Therapy and the American Society of Blood and Marrow Transplantation
• Founding Editor of Blood Advances
• President Elect of the American Society of Hematology (2025)

Dr. Negrin serves as Principal or Co-Investigator on numerous clinical trials focused on improving outcomes in hematopoietic cell transplantation, particularly in developing novel approaches to prevent and treat graft-versus-host disease and to enhance graft-versus-tumor effects. He has led research on cellular therapies, including cytokine-induced killer cells, regulatory T cells, and CAR T cells for hematologic malignancies. His work bridges basic immunology with clinical applications, translating laboratory findings into improved patient care.